JP2023018073A5 - - Google Patents

Download PDF

Info

Publication number
JP2023018073A5
JP2023018073A5 JP2022186724A JP2022186724A JP2023018073A5 JP 2023018073 A5 JP2023018073 A5 JP 2023018073A5 JP 2022186724 A JP2022186724 A JP 2022186724A JP 2022186724 A JP2022186724 A JP 2022186724A JP 2023018073 A5 JP2023018073 A5 JP 2023018073A5
Authority
JP
Japan
Prior art keywords
protein
recombinant protein
helix
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022186724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023018073A (ja
JP7500692B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2017/049894 external-priority patent/WO2018045308A1/en
Application filed filed Critical
Publication of JP2023018073A publication Critical patent/JP2023018073A/ja
Publication of JP2023018073A5 publication Critical patent/JP2023018073A5/ja
Priority to JP2024091170A priority Critical patent/JP2024123036A/ja
Application granted granted Critical
Publication of JP7500692B2 publication Critical patent/JP7500692B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2022186724A 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用 Active JP7500692B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091170A JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
JP2019512267A JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019512267A Division JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091170A Division JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Publications (3)

Publication Number Publication Date
JP2023018073A JP2023018073A (ja) 2023-02-07
JP2023018073A5 true JP2023018073A5 (https=) 2023-03-20
JP7500692B2 JP7500692B2 (ja) 2024-06-17

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Country Status (11)

Country Link
US (3) US11338033B2 (https=)
EP (1) EP3506938A1 (https=)
JP (3) JP7183149B2 (https=)
KR (2) KR20240042570A (https=)
CN (2) CN110167585B (https=)
AU (2) AU2017321883B2 (https=)
BR (1) BR112019004189A2 (https=)
CA (1) CA3035443A1 (https=)
IL (3) IL315821A (https=)
SG (2) SG11201901790YA (https=)
WO (1) WO2018045308A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10744199B2 (en) 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
SG11201901790YA (en) * 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
US20240207385A1 (en) * 2020-02-26 2024-06-27 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20240181037A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2023274860A1 (en) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
AU2022345984A1 (en) * 2021-09-16 2024-04-04 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
WO2003028632A2 (en) 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
EP1545595B1 (en) 2002-08-30 2010-07-07 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
JP5071854B2 (ja) 2005-09-12 2012-11-14 独立行政法人科学技術振興機構 微粒子−タンパク質複合体およびその作製方法、半導体装置、蛍光標識方法
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008087563A2 (en) 2006-12-29 2008-07-24 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
EP2160198A2 (en) 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
WO2008157419A2 (en) 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
US20110059130A1 (en) 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
RU2540871C2 (ru) 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
PH12012500565B1 (en) 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
CA2789945A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
EP2652496B1 (en) * 2010-12-13 2018-01-17 The University of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
IN2014CN02114A (https=) * 2011-09-20 2015-05-29 Sinai School Medicine
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
CA2857087C (en) * 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
SG11201509663PA (en) * 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
US10744199B2 (en) 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
WO2015063085A1 (en) 2013-10-28 2015-05-07 Thomas Muster Novel influenza virus vector for virotherapy
CA2950085A1 (en) * 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
US10117925B2 (en) 2014-07-10 2018-11-06 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
EP3474893A1 (en) * 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
SG11201901790YA (en) * 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Similar Documents

Publication Publication Date Title
JP2023018073A5 (https=)
JP2019537424A5 (https=)
AU2022246465B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
Lamb et al. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface
KR100715954B1 (ko) 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 ｈｂｖ 코어 항원 입자
US20230340031A1 (en) Self-assembling protein nanoparticles with built-in six-helix bundle proteins
TWI874544B (zh) 變異型rsv f蛋白質及其利用
JP7317047B2 (ja) インフルエンザウイルスワクチン及びその使用
US20120009212A1 (en) Conjugates utilizing platform technology for stimulating immune response
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
JP2022530439A (ja) 組換えインフルエンザ抗原
JP2011501950A5 (https=)
AU2018388102A1 (en) Cross-immunizing antigen vaccine and method for preparation thereof
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
US12016920B2 (en) Adjuvant based on peptide nucleic acid
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
JP2024518548A (ja) アミノ酸、ヌクレオチドおよびそれを発現するベクター、ならびにサルベコウイルス感染症の予防におけるそれらの使用
WO2025231007A1 (en) Influenza vaccine compositions and methods of making and using same
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
WO2025229334A1 (en) Oligomeric hemagglutinin antigens
US20140154282A1 (en) Conjugates utilizing platform technology for stimulating immune response
HK1193339A (en) Conjugates utilizing platform technology for stimulating immune response
CN103242426A (zh) 禽流感病毒h5n1亚型限制性ctl表位多肽及其应用